Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level
© The Author(s). 2016
Received: 17 March 2016
Accepted: 7 July 2016
Published: 20 July 2016
The poor prognosis and the limited efficacy of targeted therapy in patients with triple-negative breast cancer (TNBC) have raised the need for alternative therapies. Recent studies have demonstrated that folate receptor-alpha (FRα) may represent an ideal tumor-associated marker for immunotherapy for TNBC.
The aim of the present study was to apply a chimeric antigen receptor (CAR) approach for the targeting of FRα expressed on TNBC cells and evaluate the antitumor activity of CAR-engineered T cells in vitro and in vivo.
We found that human T cells expressing a FRα-specific CAR were potent and specific killers of TNBC cells that express moderate levels of FRα in vitro and significantly inhibited tumor outgrowth following infusion into immunodeficient mice bearing an MDA-MB-231 tumor xenograft. However, the antitumor activity of the FRα CAR T cells was modest when compared to the same CAR T cells applied in an ovarian tumor xenograft model where FRα expression is more abundant. Notably, FRα CAR T cells induced superior tumor regression in vivo against MDA-MB-231 that was engineered for overexpression of FRα.
Taken together, our results show that FRα CAR T cells can mediate antitumor activity against established TNBC tumor, particularly when FRα is expressed at higher levels. These results have significant implications for the pre-selection of patients with high antigen expression levels when utilizing CAR-based adoptive T cell therapies of cancer in future clinical trials.
KeywordsFolate receptor-alpha Triple-negative breast cancer Chimeric antigen receptor Immunotherapy
Triple-negative breast cancer (TNBC) is characterized by the limited expression of the human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR) and accounts for approximately 15 % of invasive breast cancers. Patients with TNBC do not benefit from HER2-based targeted therapy or endocrine therapy . Chemotherapy is currently the mainstay of systemic medical treatment, although patients with TNBC have a worse outcome after chemotherapy compared to breast cancer patients with other subtypes , a finding that reflects the intrinsically adverse prognosis associated with the disease. Thus, new and powerful therapies are urgently needed for TNBC patients.
A number of potential antigen targets have been validated in TNBC . Folate receptor-alpha (FRα) is highly expressed in non-mucinous tumors of epithelial origin including ovarian, breast, and lung cancers and expressed at low levels on the apical surface of a subset of polarized epithelial cells including the parotid, kidney, lung, thyroid, and breast. Specific overexpression of FRα in certain malignancies, including TNBC , with low coordinate expression in normal tissue, makes FRα an attractive target for directed therapies. In breast cancer, FRα expression can be regulated by steroid hormones, particularly estrogens [5, 6]. Specifically, 17β-estradiol has been demonstrated to down-regulate FRα expression by direct action of the ER on the P4 promoter of FRα, suggesting a negative correlation between the expression of ER and FRα. Indeed, O’Shannessy et al. demonstrated that ER-negative breast cancer samples were significantly more likely to express FRα than ER-positive cancers. Taken together, these findings rationalize the assessment of FRα as a tumor-associated antigen candidate for the targeted therapy of TNBC.
Given its cancer-centric overexpression, FRα has been an attractive candidate for targeted drug delivery using folate-conjugated therapeutic compounds that bind FRα or murine, chimeric, and humanized monoclonal antibodies (mAbs) alone or in conjugates to deliver radionuclides, T cells, and stimulatory cytokines to malignant tissue [7, 8]. Additionally, the transfer of T cells genetically redirected with a chimeric antigen receptor (CAR) specific for FRα is an attractive technology that is actively being investigated [9, 10]. The CAR approach combines the antigen specificity of an antibody with the ability of T cells to mediate the killing of tumor cells in a single fusion molecule. CAR-modified T cells actively and specifically target their specified antigen and have the capacity to persist as memory cells in vivo [9, 10]. As such, CAR-modified T cells that target tumor-associated antigens (TAAs), such as FRα, may be more effective than mAbs in generating durable tumor responses. Here, we generated a FRα-specific CAR with an intracellular CD27 co-stimulatory signaling domain and evaluated the therapeutic efficacy of T cells transduced to express this CAR in a murine xenograft model of human TNBC. We demonstrate that FRα-specific CAR T cells have the capacity to inhibit human TNBC growth in vivo and that more robust tumor regression is achievable when the TNBC cells overexpress surface FRα protein.
Lentivirus packaging was executed using the immortalized normal fetal renal 293T cell line purchased from ATCC. Human cell lines used in immune-based assays include the established human ovarian cancer cell lines SKOV3 and C30 and breast cancer cell lines T47D, SKBR3, MCF7, MDA-231, MDA-436, MDA-468, MDA-453, and BT549. For bioluminescence assays, the cancer cell lines were transfected to express firefly luciferase (fLuc). The mouse malignant mesothelioma cell line, AE17 (kindly provided by Steven Albelda, University of Pennsylvania), was used as antigen negative control. All cell lines were maintained in R10 medium: RPMI-1640 supplemented with 10 % heat-inactivated FBS, 100 U/mL penicillin, 100 mg/mL streptomycin sulfate, and 10 mmol/L HEPES.
CAR construction and lentivirus production
Human T cells and transfection
Primary human T cells, purchased from the Human Immunology Core at University of Pennsylvania, were isolated from healthy, normal donors following leukapheresis by negative selection. All T cell samples were collected under a protocol approved by a University Institutional Review Board, and written informed consent was obtained from each healthy, normal donor. T cells were cultured in R10 medium and stimulated with anti-CD3 and anti-CD28 monoclonal antibody (mAb)-coated beads (Invitrogen). Approximately 18 to 24 h after activation, human T cells were transduced using a spinoculation procedure. Briefly, 0.5 × 106 T cells were infected with a multiplicity of infection (MOI) of 5 of the MOv19-27z vector. A mixture of cells and vectors were centrifuged at room temperature for 90 min (2500 rpm) in a table-top centrifuge (Sorvall ST 40). After the engineered T cells were rested, as determined by decreased growth kinetics and cell size which is measured using the Multisizer 3 Coulter Counter (Beckman Coulter), the rested T cells were then used for functional analysis.
Flow cytometric analysis
The following fluorochrome-conjugated mAbs, purchased from BD Biosciences, were used for phenotypic analysis: APC-Cy7 anti-human CD3, fluorescein isothiocyanate (FITC) anti-human CD4, APC anti-human CD8, PE-anti-human CD45, and PE anti-human CD137. 7-Aminoactinomycin D (7-AAD) was used for viability staining. For the in vivo mouse T cell transfer experiments, peripheral blood was obtained via retro-orbital bleeding and stained for the presence of human CD45, CD4, and CD8 T cells. Gating specifically on the human CD45+ population, the CD4+ and CD8+ subsets were quantified using TruCount tubes (BD Biosciences) with known numbers of fluorescent beads as described in the manufacturer’s instructions. Tumor cell lines and enzymatically digested MDA-231 tumor cell surface expression of FRα was measured using human PE-FRα mAb (R&D Systems, Inc.) and Quanti-Brite PE beads (BD Bioscience). The FRα PE-conjugated antibody was used at a 1:1 PE/protein ratio for the quantitative analysis of surface FRα expression. FRα antigen copy number per tumor cell was evaluated by comparing the mean fluorescence intensity (MFI) versus the number of known PE molecules per bead. A calibration curve was constructed per cell line to calculate the mean number of PE molecules per cell for the FRα+ cell population. Mouse mesothelioma cell line AE17 was used as a negative control, and the background human FRα receptors/cell values measured on AE17 were subtracted from the FRα receptors/cell values detected on breast cancer cell lines.
FRα CAR surface expression was evaluated using recombinant FRα-Fc protein (R&D Systems) followed by PE-labeled anti-human IgG Fc gamma-specific antibody (eBioscience) or biotin-labeled goat anti-mouse IgG F(ab′)2 fragment followed by streptavidin-APC. For intracellular cytokine staining, T cells were stimulated in R10 media containing phosphomolybdic acid (PMA) (30 ng/mL) (Sigma-Aldrich), ionomycin (500 ng/mL) (Sigma-Aldrich), and monensin (GolgiStop) (1 μL/mL) (BD Biosciences) in a cell incubator with 10 % CO2 at 37 °C for 4 h. Cytokine production in CAR T cells was determined by co-culturing CAR T cells with FRαpos ovarian cancer cells for 5 h. After the cell surface markers were stained, the cells were then fixed and permeabilized using Cytofix/Cytoperm and Perm/Wash buffer (eBioscience) according to the manufacturer’s instructions. The cells were then stained with the following fluorescence-conjugated cytokine antibodies: PE anti-human interferon-gamma (IFN-γ), Pacific Blue anti-human TNF-α, and FITC anti-human IL-2. All flow cytometry was conducted using a BD FACSCanto II flow cytometer (BD Biosciences), and flow cytometric data were analyzed with FlowJo version 7.6.1 software (Tree Star, Ashland, OR).
Cytokine release assays
Cytokine release assays were performed by co-culturing 1 × 105 T cells with 1 × 105 target cells in triplicate in a 96-well flat bottom plate in a total volume of 200 μL R10 media. After 20–24 h, co-culture supernatants were collected and ELISA (Biolegend, San Diego) was performed, according to the manufacturer’s instructions, to measure the secretion of IFN-γ. The values shown represent the mean of triplicate wells.
For cell-based bioluminescence assays, 5 × 104 firefly luciferase (fLuc)-expressing tumor cells were cultured with R10 media in the presence of different T cell ratios in a 96-well Microplate (BD Biosciences). After incubation for ~20 h at 37 °C, each well was filled with 50 μL of DPBS resuspended with 1 μL of d-luciferin (0.015 g/mL) and imaged with the Xenogen IVIS Spectrum. Tumor cell viability percentage was calculated as the mean luminescence of the experimental sample minus background divided by the mean luminescence of the input number of target cells used in the assay minus background times 100. All data are represented as a mean of triplicate wells.
Xenograft model of TNBC and ovarian cancer
All animals were obtained from the Stem Cell and Xenograft Core of the Abramson Cancer Center, University of Pennsylvania. NOD/SCID/γ-chain−/− (NSG) mice (6–12 weeks old) were bred, treated, and maintained under pathogen-free conditions in-house under University of Pennsylvania IACUC-approved protocols. To establish a TNBC model, 6- to 12-week-old female NSG mice were inoculated subcutaneously (s.c.) on the flank with 3 × 106 MDA-231 fLuc+ or MDA-231.FR fLuc cells on day 0. For the ovarian cancer model, NSG mice were inoculated s.c. on the flank with 5 × 106 SKOV3 fLuc+ cells. After the tumors become palpable at about 3 weeks, primary human T cells were activated and transduced as described above. After the primary human T cells were expanded for 2 weeks and the mouse tumor burden was about 200–300 mm3, the mice were treated with the T cells. The route, dose, and timing of T cell injections are indicated in the individual figure legends. Tumor dimensions were measured with calipers and tumor volumes calculated using the formula V = 1/2(length × width2), where length is the greatest longitudinal diameter and width is the greatest transverse diameter. Animals were imaged prior to T cell transfer and about every week thereafter to evaluate tumor growth. Photon emission from fLuc+ cells was quantified using the “Living Image” software (Xenogen) for all in vivo experiments. Approximately 40 days after the first T cell injection, the mice were euthanized and the tumors were resected immediately in order to calculate the tumor volumes.
Tumor growth was also monitored using bioluminescence imaging (BLI). BLI was conducted using Xenogen IVIS imaging system. The photons emitted from fLuc-expressing cells within the animal body were quantified using Living Image software (Xenogen). Briefly, mice bearing MDA-231 fLuc+ or MDA-231.FR fLuc+ tumor cells were injected intraperitoneally (i.p.) with d-luciferin (150 mg/kg stock, 100 μL of d-luciferin per 10 g of mouse body weight) suspended in PBS and imaged under isoflurane anesthesia after 5~10 min. A pseudocolor image representing light intensity (blue, least intense; red, most intense) was generated using Living Image. BLI findings were confirmed at necropsy.
The data are reported as means and standard deviations (SDs). Statistical analysis was performed using two-way repeated-measure analysis of variance (ANOVA) for the tumor burden (tumor volume, photon counts). Student’s t test was used to evaluate differences in absolute numbers of transferred T cells, cytokine secretion, and specific cytolysis. GraphPad Prism 5.0 (GraphPad Software) was used for the statistical calculations, where a p value of p < 0.05 was considered significant.
Construction and expression of FRα-specific CAR
A FRα-specific CAR-encoding lentivirus construct was generated comprised of the anti-human FRα-specific MOv19 scFv  linked to a CD8α hinge and transmembrane region, followed by a CD27 intracellular signaling motif in tandem with the CD3ζ signaling moiety, and referred to as MOv19-27z (Fig. 1a). Primary human CD3+ T cells were efficiently transduced with CAR lentiviral vectors with reproducible transduction efficiencies of ~80 % (Fig. 1b). Surface expression of the FRα CAR on CD4+ and CD8+ T cells was detectable using recombinant FRα protein staining (Fig. 1c), demonstrating positive CAR expression and antigen binding capacity.
FRα is expressed on the surface of TNBC cell lines
FRα CAR T cells specifically recognize FRαpos TNBC cell lines in vitro
In addition to the above assays, representative fluorescence-activated cell sorter (FACS) plots of 5-h intracellular expression of proinflammatory cytokines by FRα CAR T cells in response to FRαpos TNBC cells are shown (Fig. 3c). Th1 cytokines including IFN-γ, TNF-α, and IL-2 were exclusively expressed in FRα CAR T cells and not in UNT control T cells, when incubated with the FRαpos MDA-231 TNBC cell line. PMA/ionomycin-treated T cells served as positive controls for T cell-stimulated cytokine production.
FRα CAR T cells have antitumor activity against MDA-231 in vitro and in vivo
To assess the antitumor activity of CAR T cells targeting FRαpos tumor in vivo, we first evaluated the potency of FRα CAR T cells using a xenograft mouse model of TNBC tumor. Immunodeficient non-obese diabetic/severe combined immunodeficient/IL-2γcnull (NSG) mice received subcutaneous inoculation of firefly luciferase (fLuc+) FRαpos human TNBC MDA-231 cells on the hind flank and received intravenous (I.V.) injections of 107 CAR+ T cells on days 40 and 46 after tumor inoculation, when tumors were ~250 mm3 in size and evident by bioluminescence imaging (BLI). Infused FRα-specific MOv19-27z CAR T cells mediated significant, albeit modest, reduction in tumor progression compared to the control mice treated with untransduced T cells (p = 0.01) or with anti-CD19 CAR T cells (p = 0.035), as measured by caliper-based tumor size (Fig. 4b).
We next measured the persistence of the transferred human T cells in vivo to determine whether modest antitumor activity was associated with poor T cell engraftment. Peripheral blood was obtained from MDA-231-bearing NSG mice treated with IV injections of T cells on day 60, 14 days after the last dose of transferred T cells, and quantified for the presence of human CD4+ and CD8+ T cells. Mice that received FRα-specific MOv19-27z T cells had readily detectable circulating human CD4+ and CD8+ T cells with significantly higher cell counts than those observed in mice treated with anti-CD19 CAR or untransduced T cells (Fig. 4c; p = 0.008 and p = 0.002, respectively), indicating that tumor antigen recognition drives the survival of the adoptively transferred FRα-specific CAR T cells in vivo.
We next assayed for FRα protein expression on residual tumors after treatment with untransduced, anti-CD19 CAR or FRα-specific CAR T cells, to determine whether tumor outgrowth in FRα CAR-treated mice was a byproduct of immune pressure and selective growth of FRα-negative cancer cells. MDA-231 tumors retained a stable FRα expression profile (Additional file 2: Figure S2), indicating that antigen loss did not occur after CAR T cell treatment in this TNBC xenograft model.
FRα CAR T cells preferentially kill antigen overexpressing tumor cells
FRα CAR T cells induce rapid tumor regression of TNBC overexpressing FRα in vivo
Although triple-negative breast cancer (TNBC) comprises approximately 15 % of all breast cancer subtypes, its aggressive biology and lack of specific systemic regimen or targeted therapy mandates the search for novel treatments specific for TNBC. Folate receptor-alpha (FRα; FOLR1) is a glycosyl-phosphatidyl inositol (GPI)-anchored protein that is overexpressed at both the protein and mRNA levels in TNBC , where it serves a biological role in TNBC cell growth and folate uptake. Strong FRα immunohistochemical (IHC) staining is highly associated with poor outcome in breast cancer patients , and while approximately 30 % of breast cancers express FRα, 70–80 % of stage IV metastatic TNBC tumors express FRα across multiple subtypes . Importantly, the increased expression of FRα is associated with a significantly worse clinical outcome in TNBC . Thus, the rationale for targeting FRα in TNBC is sound. Interestingly, endogenous immune responses against FRα are evident in cancer patients. For instance, Knutson et al.  demonstrated that immunity to FRα is prevalent in patients with breast and ovarian cancers where FRα-reactive lymphocytes having been identified in patients with these cancers and attempts to bolster this natural immunity are being investigated in preclinical and ongoing clinical trials in ovarian cancer and lung cancer [20, 21]. This led to our hypothesis that TNBC could be effectively targeted with immune-based cancer treatment using CAR T cells, an approach that has shown great utility on the treatment of hematological malignancy . CAR T cell therapy represents a rapid approach to generate and apply a large number of antigen-specific T cells for the treatment of cancer, and in previous studies, we developed FRα-specific CAR T cells that demonstrated potent effects on human ovarian cancer in preclinical models [9, 10]. We therefore sought to utilize FRα CAR T cells to target TNBC.
Consistent with IHC assay results reported by others [4, 17, 18], we found positive surface expression of FRα protein on all (5/5) human TNBC cell lines tested by flow cytometry. FRα expression was largely moderate on these TNBC lines; however, IHC findings demonstrate that FRα protein can be expressed at high, intermediate, or low levels in TNBC, and as with primary breast tumors, the abundance of FRα mRNA varies among TNBC cell lines, with a subset expressing high levels . As we showed earlier, FRα-specific CAR T cells are sensitive in vitro to FRα protein displayed on the cancer cell surface at a wide range of levels [9, 10]. In the current study, primary human T cells expressing a FRα-specific CAR recognized all human TNBC cell lines expressing FRα at different levels. FRα-specific T cells exhibited polyfunctionality in their ability to secrete IFN-γ, TNF-α, and IL-2 upon stimulation with FRα+ tumor cells. FRα CAR T cells also displayed potent cytolytic capacity in vitro against FRα+ TNBC cell lines. These in vitro tumor killing findings further support the notion that FRα has promise as a novel immunotherapy target for TNBC, which currently lacks effective targeted therapy. Importantly, two injections of FRα CAR T cells exhibited in vivo antitumor effects in a highly invasive and metastatic MDA-MB-231 xenograft model of human TNBC. Given the natural range of FRα protein expression level in TNBC, we postulated that the response to CAR T cell therapy may be more pronounced in patients with tumors expressing higher levels of FRα. Indeed, our preclinical studies show that the antitumor activity of FRα CAR T cells correlates with the level of surface antigen expressed by tumor cells, as demonstrated by the more dramatic tumor regressions mediated by CAR T cells in mice bearing MDA-231 TNBC tumors in which FRα was expressed at a high level.
Our results rationalize the application of FRα CAR T cell therapy in patients with TNBC whose tumors express FRα, particularly at a high level. It is notable that the FRα gene is positively regulated by the glucocorticoid receptor agonist, dexamethasone, at the transcriptional (P4 promoter) level and this profound regulation is further potentiated by inhibiting histone deacetylase (HDAC) . This observation supports the notion that the efficacy of FRα CAR T cell therapy in TNBC patients with low to intermediate tumoral FRα levels may be improved in combination with dexamethasone and HDAC inhibitors that enhance FRα gene expression; however, additional preclinical studies of cell surface expression of FRα would be required to confirm this finding in vitro and in vivo, as well as their effects on normal tissue organ expression.
As an alternative approach to improve CAR T cell therapy for TNBC, simultaneous co-targeting of two different tumor-associated antigens may be applied to broaden the immune response and induce tumor elimination. For instance, like FRα, mesothelin, another GPI-linked cell surface glycoprotein present on mesothelial cells, is overexpressed in TNBC and has been shown to be an attractive immunotherapy target for CAR T cells . We previously constructed a fully human anti-mesothelin CAR and showed that CAR-redirected T cells efficiently kill mesothelin-expressing tumors in vitro and in vivo . Therefore, co-administration of FRα CAR T cells and mesothelin CAR T cells may provide superior antitumor effects in TNBC and also address potential issues of tumor antigen heterogeneity and antigen loss, which has been previously reported [26, 27]. In this line, we have previously established proof of principle for the application of bispecific CAR T cells with specificity for both mesothelin and FRα . However, Anurathapan et al.  demonstrated optimal antitumor effects using two different antigen-specific CARs simultaneously, though this was insufficient to achieve a complete response. Small numbers of residual tumor cells were observed that appeared to express the targeted antigens and were resistant to repetitive T cell treatment, likely due to the low level of antigen expression determining tumor susceptibility to CAR T cells. Similarly, in a multicenter trial  of a novel FRα-targeted agent (EC145) in advanced, FRα-positive adenocarcinoma of the lung, there was an overall survival advantage and superior clinical benefit response for patients who had high expression of FRα on their tumors compared with those who had tumors with intermediate FRα expression. Based on these results, a phase II trial (clinicaltrials.gov/NCT01577654) evaluating the activity of EC145 versus EC145 plus docetaxel versus docetaxel alone in FRα high tumors has been initiated. Collectively, results from these studies suggest that pre-selection of patients with a high-level antigen expression could improve clinical response rates.
In the clinic, another T cell-based immunotherapy approach utilizing bispecific T cell engager (BiTE) is also under investigation [31, 32]. BiTEs provide a conventional drug approach in terms of storage, dosage, and delivery system; however, BiTEs have a short half-life and have to be given as a continuous infusion, which can be associated with systemic toxicities . In addition, BiTEs lack active biodistribution once infused and may not penetrate tissue planes . Compared with the BiTE approach, CAR T cell therapy has several advantages for TNBC and other cancers. CAR T cells can recognize and lyse cells bearing a very low level of target antigen, and CAR T cells can persist long term in vivo. Since our human FRα CAR T cells do not cross-react against mouse FRα protein, the potential for toxicity of this approach in the TNBC mouse model cannot be determined. Importantly, however, various strategies are being developed to create safer, regulatable CARs that control and/or minimize potential toxicity [34, 35].
While increased expression of FRα is associated with a poor clinical outcome in TNBC , FRα expression may vary by TNBC subtype and be associated with disease stage. Future studies will be required to determine the minimal and maximal threshold of FRα expression for activation and effective lysis by FRα CAR T cells upon stimulation with the TNBC cell lines or autologous tumor cells. Such results might aid in determining which patients may best benefit from FRα CAR T cell therapy and help determine the potential for off-tumor targeting of healthy tissues that may express low levels of antigen.
We report the first demonstration of an in vivo antitumor response against established human TNBCxenografts using FRα-redirected CAR T cell therapy, with increased sensitivity observed against tumors bearing higher FRα protein levels. We therefore conlude that pateints with TNBC that expresses a high level of FRα protein may benefit from FRα-redirected CAR T cell therapy. More so, our preclinical studies serve to further accelerate the translation of FRα-targeted immunotherapies, including FRα CAR T cell therapy, to the clinic for TNBC.
The authors gratefully acknowledge Drs. Lin Zhang, Qihong Huang, and Laura Barrio Real for providing the TNBC cell lines.
This work was supported by grants from the Basser Center for BRCA Research (DJP) for breast cancer studies, the Ovarian Cancer Research Foundation (DJP) for CAR T cell construction, and a generous gift from the Bethesda Foundation for in vitro assays.
Availability of data and materials
Due to our internal policy and those governing an alliance between Novartis and the University of Pennsylvania on CAR T cells in oncology, the raw data cannot be shared.
DJP and DS initiated and designed the in vitro and in vivo studies. DS and MP performed the preclinical animal studies. DS, QY, and JAC performed the in vitro experiments. MF aided in the construction of the vectors. DS, JAC, and DJP prepared the manuscript. All authors read and approved the final manuscript.
DJP holds patents in the area of CAR T cell therapy for oncology. The remaining authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
All animals were obtained from the Stem Cell and Xenograft Core (SCXC) of the Abramson Cancer Center, University of Pennsylvania. Mice were bred, treated, and maintained under pathogen-free conditions in-house under University of Pennsylvania IACUC-approved protocols and as mandated by federal law and regulations. The experimental protocol was conducted in accordance with the recommendations of the Guide for Care and Use of Laboratory Animals with respect to restraint, husbandry, surgical procedures, feed and fluid regulation, and veterinary care. The animal care and use program at the University of Pennsylvania is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–48.View ArticlePubMedGoogle Scholar
- Tan DS, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat. 2008;111(1):27–44.View ArticlePubMedGoogle Scholar
- Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007;8(3):235–44.View ArticlePubMedGoogle Scholar
- O’Shannessy DJ, et al. Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease. Springerplus. 2012;1(1):1–9.View ArticleGoogle Scholar
- Rochman H, Selhub J, Karrison T. Folate binding protein and the estrogen receptor in breast cancer. Cancer Detect Prev. 1985;8(1-2):71.PubMedGoogle Scholar
- Kelley KM, Rowan BG, Ratnam M. Modulation of the folate receptor α gene by the estrogen receptor mechanism and implications in tumor targeting. Cancer Res. 2003;63(11):2820–8.PubMedGoogle Scholar
- Xia W, Low PS. Folate-targeted therapies for cancer. J Med Chem. 2010;53(19):6811–24.View ArticlePubMedGoogle Scholar
- Clifton GT, et al. Folate receptor α: a storied past and promising future in immunotherapy. Human Vaccines. 2011;7(2):183–90.View ArticlePubMedGoogle Scholar
- Song D-G, et al. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood. 2012;119(3):696–706.View ArticlePubMedGoogle Scholar
- Song D-G, et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 2011;71(13):4617–27.View ArticlePubMedPubMed CentralGoogle Scholar
- Milone MC, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17(8):1453–64.View ArticlePubMedPubMed CentralGoogle Scholar
- Parry RV, et al. CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. J Immunol. 2003;171(1):166–74.View ArticlePubMedGoogle Scholar
- Figini M, et al. Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor. Cancer Immunol Immunother. 2009;58(4):531–46.View ArticlePubMedGoogle Scholar
- Wolfl M, et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood. 2007;110(1):201–10.View ArticlePubMedPubMed CentralGoogle Scholar
- Siu MK, et al. Paradoxical impact of two folate receptors, FRα and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome. PLoS One. 2012;7(11):e47201.View ArticlePubMedPubMed CentralGoogle Scholar
- Necela BM, et al. Folate receptor-α (FOLR1) expression and function in triple negative tumors. PLoS One. 2015;10(3):e0122209.View ArticlePubMedPubMed CentralGoogle Scholar
- Hartmann LC, et al. Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer. 2007;121(5):938–42.View ArticlePubMedGoogle Scholar
- Zhang Z. et al. Folate receptor α associated With triple-negative breast cancer and poor prognosis. Arch Pathol Lab Med. 2013.Google Scholar
- Knutson KL, et al. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol. 2006;24(26):4254–61.View ArticlePubMedGoogle Scholar
- Konner JA, et al. Farletuzumab, a humanized monoclonal antibody against folate receptor α, in epithelial ovarian cancer: a phase I study. Clin Cancer Res. 2010;16(21):5288–95.View ArticlePubMedGoogle Scholar
- Thomas A, Maltzman J, Hassan R. Farletuzumab in lung cancer. Lung Cancer. 2013;80(1):15–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Maude SL, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17.View ArticlePubMedPubMed CentralGoogle Scholar
- Tran T, et al. Enhancement of folate receptor α expression in tumor cells through the glucocorticoid receptor: a promising means to improved tumor detection and targeting. Cancer Res. 2005;65(10):4431–41.View ArticlePubMedGoogle Scholar
- Tchou J, et al. Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat. 2012;133(2):799–804.View ArticlePubMedGoogle Scholar
- Lanitis E, et al. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol Ther. 2012;20(3):633–43.View ArticlePubMedGoogle Scholar
- Riker A, et al. Immune selection after antigen-specific immunotherapy of melanoma. Surgery. 1999;126(2):112–20.View ArticlePubMedGoogle Scholar
- Grupp SA, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–18.View ArticlePubMedPubMed CentralGoogle Scholar
- Lanitis E, et al. Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res. 2013;1(1):43–53.View ArticlePubMedPubMed CentralGoogle Scholar
- Anurathapan U et al. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2013.Google Scholar
- Edelman MJ, et al. Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung. J Thorac Oncol. 2012;7(10):1618–21.View ArticlePubMedGoogle Scholar
- Wu J, et al. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol. 2015;8(1):1.View ArticleGoogle Scholar
- Fan G, et al. Bispecific antibodies and their applications. J Hematol Oncol. 2015;8(1):1.View ArticleGoogle Scholar
- Stone JD, et al. A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell engagers (BiTEs). Oncoimmunology. 2012;1(6):863–73.View ArticlePubMedPubMed CentralGoogle Scholar
- Rodgers DT, et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci. 2016;113(4):E459–68.View ArticlePubMedPubMed CentralGoogle Scholar
- Wu CY, et al. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science. 2015;350(6258):aab4077.View ArticlePubMedPubMed CentralGoogle Scholar